A cell-permeable mycotoxin that inhibits sphingolipid biosynthesis in rat kidney and in liver microsomes by inhibition of sphingosine N-acyltransferase (ceramide synthase; IC₅₀ = 100 nM). Preferentially inhibits sphingomyelin biosynthesis in neuronal cells. Exhibits carcinogenic properties.

Fumonisin B₁ is a neurotoxin and a phytotoxin. A cell-permeable mycotoxin that inhibits sphingolipid biosynthesis in rat kidney and in liver microsomes by inhibition of sphingosine N-acyltransferase (ceramide synthase) (IC₅₀ = 100 nM). Cellular effects also appear to be induced by micromolar levels of FB₁. Because it inhibits ceramide synthase activity, it elevates cellular levels of sphingoid bases, including sphinganine, resulting in overall inhibition of sphingolipid biosynthesis. Preferentially inhibits sphingomyelin biosynthesis in neuronal cells. Has carcinogenic properties.

Primary Target
ceramide synthase

Target IC₅₀: 100 nM against sphingosine N-acyltransferase (ceramide synthase)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.

Wu, W.I., et al. 1995. J. Biol. Chem.270, 13171.
Riley, R.T., et al. 1994. J. Nutr. 124, 594.
Wolf, G. 1994. Nutr. Rev. 52, 246.
Merrill, A.H. Jr., et al. 1993. Adv. Lipid Res.26, 215.
Merrill, Jr., A.H., et al. 1993. J. Biol. Chem.268, 27299.
Voss, K.A., et al. 1993. Nat. Toxins1, 222.
Wang, E., et al. 1991. J. Biol. Chem.266, 14486.
Harrison, L.R., et al. 1990. J. Vet. Diag. Invest. 2, 217.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Carcinogenic / Teratogenic (D)